Academic Health Center
Stay Connected
research-and-clinical-trials

Dental Therapy: Good news for Minnesota safety net clinics

Dental therapy, the newest oral healthcare profession in Minnesota, has firm roots in the state’s safety net clinics, found new research from the University of Minnesota School of Dentistry.

Findings from the study indicate dental therapists are being used in innovative and diverse ways, allowing the dental therapy profession to continue to evolve in the way it addresses specific oral health care needs.

Read more
u-of-m-voices

Dental Therapy: Filling the gaps in dental disparities

The next time you’re in a dental office, there’s a chance your clinician might say, “Hi, I’m the dental therapist who will be working with you today.” More of these providers are entering the market each year thanks to innovative programs like the one found at the University of Minnesota. As a result, more and more Minnesotans are getting exposed to dental therapists.

But some patients still have questions around what a dental therapist actually is and the type of work they’re licensed to perform. Here’s some quick background.

Read more
research-and-clinical-trials

U of M researchers lead development of first evidence-based diagnostic criteria for TMD

The first evidence-based diagnostic criteria has been developed to help health professionals better diagnose temporomandibular disorders (TMD), a group of often-painful jaw conditions that affect an estimated 10 to 15 percent of Americans. The international effort was led by the University of Minnesota School of Dentistry.

The Diagnostic Criteria for Temporomandibular Disorders (DC/TMD), developed by a collaborative team of researchers in North America, Europe and Australia, are professional recommendations on how best to detect and assess jaw joint (TMJ) and jaw muscle problems – as well as headaches related to TMD.

Read more
research-and-clinical-trials

New anti-HIV drug target identified by University of Minnesota researchers

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

Complete findings are printed in today’s issue of The Journal of Virology.

The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis.

Read more
expert-perspectives

AHC game changer: Julie Olson

What do you want to be when you grow up?

When most kids hear that question they respond with “professional athlete,” “police officer,” or “an astronaut”. But not Julie Olson, who started conducting research at the University of Minnesota in September. From an early age she knew what she wanted to be.

Read more
research-and-clinical-trials

Drug design success propels efforts to fight HIV with a combination of two FDA-approved drugs

A University of Minnesota research team featuring researchers from the Institute for Molecular VirologySchool of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found “online first” in the journal Antiviral Chemistry & Chemotherapy.

Read more